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Glycoproteins perform extra- and intracellular functions in innate and adaptive immu-
nity by lectin-based interactions to exposed glyco-determinants. Herein, we document
and mechanistically explain the formation of subcellular-specific N -glycosylation determi-
nants on glycoproteins trafficking through the shared biosynthetic machinery of human
cells. LC-MS/MS-based quantitative glycomics showed that the secreted glycoproteins
of eight human breast epithelial cells displaying diverse geno- and phenotypes con-
sistently displayed more processed, primarily complex type, N -glycans than the high-
mannose-rich microsomal glycoproteins. Detailed subcellular glycome profiling of pro-
teins derived from three breast cell lines (MCF7/MDA468/MCF10A) demonstrated that
secreted glycoproteins displayed significantly more α-sialylation and α1,6-fucosylation, but
less α-mannosylation, than both the intermediately glycan-processed cell-surface glycopro-
teomes and the under-processed microsomal glycoproteomes. Subcellular proteomics and
gene ontology revealed substantial presence of endoplasmic reticulum resident glycopro-
teins in the microsomes and confirmed significant enrichment of secreted and cell-surface
glycoproteins in the respective subcellular fractions.The solvent accessibility of the glycosy-
lation sites on maturely folded proteins of the 100 most abundant putative N -glycoproteins
observed uniquely in the three subcellular glycoproteomes correlated with the glycan
type processing thereby mechanistically explaining the formation of subcellular-specific N -
glycosylation. In conclusion, human cells have developed mechanisms to simultaneously
and reproducibly generate subcellular-specific N -glycosylation using a shared biosynthetic
machinery.This aspect of protein-specific glycosylation is important for structural and func-
tional glycobiology and discussed here in the context of the spatio-temporal interaction of
glyco-determinants with lectins central to infection and immunity.
Keywords: N -glycosylation, solvent accessibility, N -glycome, subcellular location, glycoproteome, glycosylation
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INTRODUCTION
Significant parts of the human genome and cellular energy are ded-
icated to produce and regulate protein glycosylation (1). Hence, it
is no surprise that this abundant post-translational modification is
important in a wide spectrum of biological processes to maintain
cellular homeostasis (2). Dysregulation of protein glycosylation
is a cause and/or effect of numerous pathological conditions
including, but not limited to, congenital disorder of glycosylation
(3), cystic fibrosis (4), inflammation (5), auto-immunity (6), and
cancer (7). The extracellular location of secreted and cell-surface-
tethered proteins carrying N -linked glycosylation is ideal for facil-
itating molecular interactions with the surrounding environment
(8). Intracellular functions of N -glycoproteins are also known
(9, 10). The terminal determinants of host N -glycans (so-called
“self” and “altered self” in disease) are recognized by endogenous
and exogenous glycan-binding proteins commonly called lectins.
Interactions between lectins and N -glycans are central in innate
and adaptive immunity (11). Important examples include the C-
type lectins, which may be crudely divided into lectins having
affinity for α-mannose/α-fucose-terminated N -glycans including
dendritic cell-specific intercellular adhesion molecule-3-grabbing
non-integrin (DC-SIGN), macrophage mannose receptors and
Langerin (12), and lectins having affinity for galactose/GalNAc
terminating glycans such as macrophage galactose lectin and DC-
asialoglycoprotein receptor (13, 14). In addition, siglecs (I-type
lectins) and galectins (S-type lectins) are important for facilitating
a functional immune response (15).
The human N -glycosylation biosynthetic machinery is rela-
tively well understood (16, 17). In brief, the synthesis is ini-
tiated by the transfer of common immature glycan precursors
i.e., Glc3Man9GlcNAc2 to conserved sequons (NxT/S, x 6=P) on
translocating polypeptide chains. The glycan precursor is then
remodeled through sequential trimming and elongation by spe-
cific glycosidases and glycosyltransferases located in the endoplas-
mic reticulum (ER) and the cis-, medial, and trans-Golgi, respec-
tively. This series of enzymatic processes first results in the traffick-
ing N -glycoproteins being comprised of attached high-mannose-
type N -glycans, which progresses to the hybrid- and complex-type
stage if sufficient interactions with the processing enzymes occur
(17). The Golgi-based N -glycan processing, including the forma-
tion of glycan types and the addition of terminal determinants
such asα-fucosylation andα-sialylation,occurs on maturely folded
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glycoproteins (18, 19). An extensive and reproducible repertoire of
N -glycans is usually present on a given glycosylation site (20). This
N -glycan microheterogeneity on proteins results from incom-
plete processing by the multiple competing enzymatic reactions
that can be influenced by cellular factors including the avail-
ability of nucleotide sugars, glycosylation enzyme activity, and
glycoprotein trafficking time through the biosynthetic machin-
ery. Such cellular factors contribute to cell- and tissue-specific
N -glycosylation (21). Importantly, the structures of the individ-
ual glycoproteins trafficking through the glycosylation machinery
dramatically influence the degree of N -glycan processing creat-
ing protein- and site-specific N -glycosylation (22). By thorough
literature-based curation of published site-specific glycoprofiling
data of mammalian N -glycoproteins, we recently confirmed that
several structural features including glycan type formation, α1,6-
(core) fucosylation, and β1,4/6-GlcNAc branching of N -glycans
are strongly correlated with the solvent accessibility of the gly-
cosylation sites of maturely folded glycoproteins (19). As such,
extensive N -glycan processing was observed for proteins display-
ing solvent accessible glycosylation sites relative to spatially hidden
sites. Thus, differential site accessibility can explain how glycopro-
teins produced simultaneously in the same cell, and even sequons
on the same glycoproteins, can present widely different N -glycan
structural repertoires.
Considering the importance of protein- and site-specific N -
glycosylation in many aspects of glycobiology including glyco-
immunology, we here seek to further explore this feature in the
context of the multiple subcellular glycoproteomes that traffic
through the shared glycosylation machinery in the secretory path-
way of human cells, yet end up at different cellular locations.
Due to the functional implications of both intra- and extra-
cellular N -glycoproteins, we focus on the secreted, cell-surface,
and intracellular glycoproteomes, the latter fraction largely rep-
resented by microsomal proteins (23). Understanding, how the
subcellular glycoproteomes are generated and regulated under
normal and altered physiological conditions of the cell is valuable
to the understanding of their involvement in immune biology.
Recent analytical developments in glycomics (24–27) and glyco-
proteomics (28–31) have, together with more conventional pro-
teomics, enabled sensitive, and detailed system-wide investigations
of the regulation of protein N -glycosylation in immunity (32).
Using LC-MS/MS-based glycomics and proteomics on mul-
tiple subcellular fractions from a panel of human cell lines dis-
playing diverse cellular characteristics, we here document that
human cells have developed a general mechanism to reproducibly
generate vastly different N -glycan determinants on their differ-
ently located subcellular glycoproteomes that trafficked simul-
taneously through a shared biosynthetic machinery. We pro-
vide evidence that the subcellular-specific protein N -glycosylation
arises from differential solvent accessibilities of the glycosylation
sites of maturely folded glycoproteins that localize to different
subcellular compartments following the glycan processing. This
aspect of protein-specific glycosylation is discussed here in the
context of immunity and infection due to the crucial role of
endogenous and exogeneous lectins recognizing exposed self, and
altered self, glyco-determinants to facilitate the functional immune
response.
MATERIALS AND METHODS
CELLULAR ORIGIN, CULTURE CONDITIONS, AND DOUBLING TIME
Multiple human cells showing diverse geno- and phenotypical
characteristics were used to demonstrate the general nature of
the cellular mechanisms observed in this study. Human mam-
mary epithelial cells (HMEC) were purchased (product # CC-
2551, Lonza). Human breast epithelial cell lines MCF10A, MCF7,
SKBR3, MDA-MB-157 (MDA157), MDA-MB-231 (MDA231),
and HS578T as well as a human colon cancer epithelial cell
line SW480 were obtained from American Type Culture Collec-
tion (Manassas, VA, USA). HMEC was grown in HuMEC Ready
Media (Invitrogen). MCF10A was cultured in DMEM/F12 with
the addition of 5% horse serum (Invitrogen), 20 ng/mL epider-
mal growth factor (EGF) (Invitrogen), 0.5µg/mL hydrocortisone
(Sigma), 100 ng/mL cholera toxin (Sigma), and 8µg/mL insulin
(Invitrogen). Other cell lines were grown in RPMI (Sigma) sup-
plemented in 5% fetal bovine serum (FBS) (Invitrogen), 10 mM
glutamine (Invitrogen), and 10µg/mL insulin. Cells were main-
tained at 37°C in 5% CO2 for all experiments. The breast cell
lines were grown in triplicates to ~80% confluence and washed at
least four times with ice-cold phosphate buffered saline (PBS) to
remove traces of FBS and incubated in serum-free media at 37°C
in 5% CO2 for 48 h prior to subcellular fractionation.
To measure the cellular doubling times of the breast cell lines,
cells were seeded at 1.3× 104 cells/mL/well in six-well plates and
incubated overnight at 37°C in 5% CO2. Cells were counted every
24 h over a four-day period using a cell counter (Bio-Rad). The
doubling time for each cell line was determined from their expo-
nential growth phase. For overview of the investigated cells and
associated data, see Table S1 in Supplementary Material.
COLLECTION AND PREPARATION OF SUBCELLULAR GLYCOPROTEOMES
FROM BREAST CELL LINES
The secreted subcellular glycoproteomes were collected by sam-
pling 30 mL of serum-free culture media followed by centrifuga-
tion at 2,000× g to pellet any floating cells. The supernatants were
concentrated and buffer exchanged into PBS (1×) using 10,000
MWCO Amicon Ultra membranes (Millipore). Proteins were then
precipitated with nine volumes of acetone overnight at−20°C. The
pellets were stored at−80°C until further analysis.
The cell-surface subcellular glycoproteomes were isolated from
MCF7, MDA468, and MCF10A breast epithelial cell lines using a
commercial biotinylation kit (product # 89881, Pierce) to specifi-
cally biotinylate the cell-surface glycoproteins. The protocol sup-
plied by the manufacturer was followed. Briefly, monolayers of
cultured cells grown in 75 cm2 culture flasks were washed three-
times with PBS (1×) before incubation in EZ-Link sulfo-NHS-
SS-biotin in ice-cold PBS (1×) for 30 min at 4°C on a rocking
platform. The labeling reactions were terminated and the biotiny-
lated cells were washed and collected by scraping in Tris-buffered
saline (TBS) (1×), followed by centrifugation at 500× g for 3 min.
The supernatants were discarded and the cell pellets were disrupted
in manufacturer-provided lysis buffer by ultra-sonication using
five 1-s bursts with a Sonifier 450 (Branson Sonifier, Wilming-
ton, NC, USA). The cell lysates were centrifuged at 10,000× g for
2 min at 4°C. Solubilized biotinylated cell-surface proteins in the
clarified supernatants were isolated using NeutrAvidin Agarose.
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Cell-surface-bound proteins were eluted using 50 mM DTT and
precipitated with acetone overnight at −20°C. The pellets were
stored at−80°C until analysis.
The microsome (total membrane) subcellular glycoproteomes
were obtained by first removing serum-free media, thoroughly
washing cells with PBS (1×), and harvesting cells in 25 mM
Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA containing a pro-
tease inhibitor cocktail (Roche Diagnostics). The cells were ultra-
sonicated on ice for three rounds of 10-s bursts using a Sonifier
450 and centrifuged at 2,000× g for 20 min at 4°C to remove
intact cells and nuclei. The supernatants were ultra-centrifuged
at 120,000× g for 80 min after which the supernatants were dis-
carded. The microsomal membrane pellets were washed twice with
ice-cold 0.1 M sodium carbonate and resuspended in 25 mM Tris-
HCl pH 7.4, 150 mM NaCl, and 1% (v/v) Triton X-114. Samples
were phase partitioned by incubation at 37°C for 20 min, followed
by 1,000× g centrifugation for 10 min. The upper aqueous layer
was carefully removed and nine volumes of ice-cold acetone were
added to the lower detergent phase and incubated overnight at
−20°C to precipitate the proteins. The pellets were stored at−80°C
until further analysis.
The protein concentrations of the subcellular fractions
were measured using Bradford reagents (Sigma). Equal protein
amounts were precipitated in the three subcellular fractions and
the resulting pellets were solubilized in 8 M urea for spotting on
PVDF membranes for N -glycome profiling or in NuPAGE LDS
sample buffer for gel electrophoresis prior to proteome profiling.
SUBCELLULAR FRACTIONATION OF HUMAN COLON CANCER CELL
LINES
SW480 cells (5× 107) were washed twice with homogenization
buffer (20 mM HEPES, pH 7.5, and 0.25 M sucrose). Cell pellets
were resuspended to a final volume of 2 mL in homogenization
buffer and lysed using an Ultra-Turrax disperser (Ika). After a low
speed centrifugation at 1,000× g for 10 min, the supernatant was
collected as the post-nuclear fraction (PNF). The PNF was sub-
jected to ultracentrifugation at 30,000 rpm for 1 h in a SW41Ti
rotor (Beckman Coulter) to pellet the microsome. ER and Golgi-
enriched membranes were prepared as described (33). Briefly,
1 mL of PNF (usually 2.5–3 mg protein) was adjusted to 1.4 M
sucrose by adding 2 mL of 2 M sucrose. A discontinuous sucrose
gradient was made by sequentially loading 1.5 mL of 1.6 M sucrose,
3 mL PNF in 1.4 M sucrose, 3 mL of 1.2 M sucrose, and 3 mL of
0.8 M sucrose. All sucrose solutions contained 20 mM HEPES pH
7.5. Ultracentrifugation was conducted at 28,500 rpm for 2 h in a
SW41Ti rotor. Enriched-Golgi membranes were harvested at the
0.8 M/1.2 M interface. Enriched ER membranes were harvested
from the 1.4 M layer. The collected ER and Golgi membranes
were diluted by homogenization buffer to reduce concentration
of sucrose and subsequently pelleted by ultracentrifugation at
30,000 rpm for 1 h in a SW41Ti rotor. Pelleted ER- and Golgi-
enriched membranes were resuspended in 8 M urea and protein
concentrations were determined by BCA assays (Pierce).
RELEASE AND PREPARATION OF N -GLYCANS FROM SUBCELLULAR
GLYCOPROTEOMES
N -glycans were released from ~20µg secreted proteins, 50µg
cell-surface proteins, and 50µg microsome membrane proteins
as previously described (27). Briefly, protein mixtures were
immobilized on methanol-activated PVDF membranes (Milli-
pore) and allowed to dry overnight. Membrane-bound pro-
teins were incubated with 2.5 U PNGase F (Flavobacterium
meningospeticum, Roche) for 16 h at 37°C to ensure complete
release of N -glycans. Released N -glycans were incubated with
100 mM ammonium acetate (pH 5) for 1 h at RT and subsequently
dried by vacuum centrifugation. Reduction of N -glycans was per-
formed with 20µL 1 M sodium borohydride (Sigma) in 50 mM
potassium hydroxide (Sigma) for 3 h at 50°C. Reactions were
quenched with 2µL glacial acetic acid. Dual desalting was per-
formed in micro-SPE formats using strong cation exchange/C18
and carbon columns (27). Desalted N -glycans were eluted from
the carbon columns with 20µL 40% acetonitrile (ACN) contain-
ing 0.1% (v/v) trifluoroacetic acid and dried by vacuum cen-
trifugation (34). Samples were stored at −80°C if not analyzed
immediately.
DIGESTION AND PREPARATION OF PEPTIDE MIXTURES FROM
SUBCELLULAR GLYCOPROTEOMES
The subcellular glycoproteomes of the breast cells (~50µg pro-
tein/fraction) i.e., secreted, cell surface, and microsomes and of
colon cells (~10µg protein/fraction) i.e., microsome and ER- and
Golgi-enriched membrane fractions were reduced and alkylated
and subsequently in-gel (breast cells) or in-solution (colon cells)
digested. Prior to in-gel digestion, samples were loaded in 10µL
NuPAGE LDS buffer and separated on 4–12% Bis-Tris PAGE gels
(Invitrogen). Electrophoresis was performed at 200 V for 50 min.
After separation of proteins, gels were fixed in 40% (v/v) ethanol
and 10% (v/v) acetic acid for at least 2 h, stained overnight with
Coomassie Blue G250 (Bio-Rad) and destained in ultra-pure water
(Millipore). In-gel trypsin digestion of all samples was performed
from eight equal sized gel fractions. Each fraction was sliced into
1 mm pieces and placed in a 96-well plate. The gel pieces were
destained with 50% (v/v) ACN in 50 mM ammonium bicarbonate
until clear, dehydrated in 100% (v/v) ACN, and dried. Sequence-
grade porcine trypsin (Promega) (1:30 enzyme/substrate, w/w)
was used to digest the proteins overnight at 37°C. Tryptic peptide
mixtures were then collected and two rounds of gel extractions
of peptides were performed with 2% (v/v) formic acid in 50%
(v/v) ACN and 50 mM ammonium bicarbonate. The extracts
were combined, peptide mixtures dried by vacuum centrifuga-
tion, redissolved in 10µL 0.1% (v/v) formic acid, and desalted as
described below. For in-solution digestion, samples were diluted
to <1 M urea (final concentration) and trypsinized (sequence-
grade porcine trypsin, 1:40 enzyme/substrate, w/w) overnight at
37°C. Following proteolysis, the peptide mixtures were acidified by
adding formic acid to a final concentration of 0.1% (v/v). Desalted
of peptide mixtures were performed using self-packed C18 SPE
tips. Briefly, C18 tips were washed three-time with 20µL 100%
ACN, three-times with 20µL 50% (v/v) ACN in 0.1% formic acid,
and equilibrated with 50µL 0.1% (v/v) formic acid. After sam-
ple loading, tips were washed three-times with 20µL 0.1% formic
acid. Peptides were eluted with 20µL 60% (v/v) ACN in 0.1%
formic acid and 20µL 90% (v/v) ACN in 0.1% formic acid and
dried. The desalted fractions were dried and stored at−80°C until
LC-MS/MS.
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LC-MS/MS-BASED N -GLYCOMICS
N -glycans alditols were separated using a porous graphitized car-
bon (PGC) LC column [5µm (particle size) Hypercarb KAPPA,
100 mm (length)× 200µm (ID), 250 Å (pore size), Thermo Sci-
entific] using an Ultimate 3000 HPLC system (Dionex) connected
directly to an ESI-MS/MS HCT Ultra ion trap (Bruker Dalton-
ics). Separation was performed using a binary gradient solvent
system made up of solvent A (aqueous 10 mM NH4HCO3) and
solvent B (90% ACN/10 mM ammonium bicarbonate). The flow
rate was 2µL/min and a total gradient of 100 min was programed
as follows: 0–2.5% solvent B for 0–13 min; 2.5–17.5% solvent B
for 14–48 min; 17.5–50% solvent B for 48–65 min; 50–100% sol-
vent B for 65–75 min; 100% solvent B for 75–80 min; back to 0%
solvent B for 80–85 min, and 100% solvent A equilibration for
15 min. Settings for the MS/MS were as follows: drying gas flow:
6 L/min; drying gas temperature: 300°C; nebulizer gas: 12 p.s.i.;
skimmer:−40.0 V; trap drive:−99.1 V; and capillary exit:−166 V.
Smart fragmentation was used with start- and end-amplitude of
30 and 200%, respectively. Ions were detected in ion charge control
set at 100,000 ions/scan and with maximum accumulation time
of 200 ms. MS spectra were obtained in negative ion mode with
three scan events: a full scan (m/z 400–2,200) at a scan speed of
8,100 m/z/ s and data-dependent MS/MS scans after CID fragmen-
tation of the top two most intense precursor ions with an absolute
intensity threshold of 30,000 and a relative intensity threshold
of 5% relative to the base peak. Dynamic inclusion was inacti-
vated to ensure MS/MS generation of closely eluting N -glycan
isomers. Precursors were observed mainly in charge states Z =−1
and/or −2. Mass accuracy calibration of the mass spectrome-
ter was performed using a well-defined tune mix (Agilent) prior
to acquisition. N -glycans released from bovine fetuin served as
positive controls for the sample preparation and the LC-MS/MS
performance. Differences between observed and theoretical pre-
cursor and fragment masses were generally <0.2 Da. Three LC-
MS/MS technical replicates were performed for the subcellular
fractions.
LC-MS/MS-BASED PROTEOMICS
Three LC-MS/MS technical replicates of the subcellular proteomes
of the breast cells were analyzed using a Q-Exactive (Thermo Sci-
entific). Peptide mixtures in 0.1% (v/v) formic acid were loaded
onto a C18 reversed phase column packed in-house [2.7µm (parti-
cle size) HaloLink Resins, Promega, column dimensions: 100 mm
(length)× 75µm (ID)]. Separation of peptides was performed
over a 60 min gradient with the first 50 min of the linear gradi-
ent increasing from 0 to 50% in solvent B [0.1% (v/v) aqueous
formic acid/100% (v/v) ACN] and then to 85% solvent B for the
next 2 min and maintained at 85% for 8 min. The flow rate was
constant at 300 nL/min. The Easy-nLC (Thermo Scientific) was
connected directly to the nano-ESI source of the Q-Exactive. MS
full scans were acquired with resolution of 35,000 in the positive
ion mode over m/z 350–2,000 range and an automatic gain control
(AGC) target value of 1× 106. The top 10 most intense precursor
ions were then isolated for MS/MS using higher energy collisional
dissociation fragmentation at 17,500 resolution with the follow-
ing settings: collision energy: 30%; AGC target: 2× 105; isolation
window: m/z 3.0; and dynamic exclusion enabled. Precursors with
unassigned or Z =+1 charge states were ignored for MS/MS
selection.
The subcellular proteomes of the colon cells were LC-MS/MS
analyzed using a Triple TOF 5600 (ABSciex). Peptides were sep-
arated by a nanoLC system (Eksigent) on a C18 reversed phase
column [ProteCol 100 mm (length)× 150µm, (ID): 3µm (parti-
cle size), 300 Å (pore size); SGE Analytical Science] with a 90 min
gradient from 5 to 40% solvent B [90% (v/v) ACN with 0.1%
formic acid] at a constant flow rate of 600 nL/min. The top 10 most
intense precursor ions with Z =+2,+3, and+4 were selected for
MS/MS using CID fragmentation.
ANALYSIS OF N -GLYCOME LC-MS/MS DATA
N -glycome raw data for all subcellular glycoproteomes were
viewed and manually analyzed using DataAnalysis v4.0 (Bruker
Daltonics). Monoisotopic masses were obtained and searched
against GlycoMod1 to obtain possible monosaccharide compo-
sitions, which were subsequently verified manually by de novo
sequencing of corresponding MS/MS spectra and by taking
account of PGC chromatographic retention time. The glycan
type and the terminating monosaccharide determinants could
unambiguously be identified using this method (27). The relative
abundances of the observed N -glycans were determined using the
ratio of the extracted ion chromatogram (EIC) peak area of each
N -glycan species over the sum of EIC peak areas of all observed
N -glycans in the sample. This has been shown to be a reason-
ably accurate method for relative N -glycan quantitation (35).
The extent of N -glycan processing was measured by evaluating
the relative molar proportion of the relative unprocessed species
(i.e., immature mono-glucosylated glycans and high-mannose
type N -glycans) and the processed species (i.e., hybrid, complex,
and paucimannose type N -glycans) of the total N -glycome. In
addition, the degree of monosaccharide determinants including
α1,2/3/6-mannose, β1,3/4-galactose, α1,3/4/6-fucose, and α2,3/6-
sialic acid terminating N -glycans were calculated as a relative
molar abundance of both the entire N -glycome and of the poten-
tially modified N -glycan substrates (e.g., complex/hybrid-types).
Since multiple determinants may be displayed by a given N -glycan,
the total summed to more than 100%.
ANALYSIS OF LC-MS/MS-BASED PROTEOMIC DATA AND GENE
ONTOLOGY
For breast cell proteomes, raw spectra were converted to .mgf
files using Proteome Discoverer Daemon v1.3 (Thermo Scientific)
and searched against SwissProt protein database (Homo sapiens,
20,279 reviewed entries, November 2013 release) using the Global
Proteome Machine (Cyclone). The following search criteria were
used: carbamidomethylation was a fixed modification and oxida-
tion and deamidation were variable modifications for methionine
and asparagine/glutamine residues, respectively. Mass tolerances
of 10 ppm and 0.02 Da were selected for precursor and product
ions, respectively,with a maximum of two missed tryptic cleavages.
For colon cell proteomes, MS/MS spectra were extracted by
ProteinPilot v4.2 (ABSciex) and searched using Mascot v2.4.0
1http://web.expasy.org/glycomod/
Frontiers in Immunology | Immunotherapies and Vaccines August 2014 | Volume 5 | Article 404 | 4
Lee et al. Differential Asn-accessibility generates subcellular-specific N -glycosylation
(Matrix Science) against SwissProt protein database (Homo sapi-
ens, 20,253 entries, April 2013 release) using trypsin as the diges-
tion enzyme. Precursor and product ion tolerances were 20 ppm
and 0.50 Da, respectively. Oxidation of methionine residues and
carbamidomethylation of cysteine residues were used as variable
modifications.
Scaffold v4.2.1 (Proteome Software) was used to validate
MS/MS-based peptide and protein identifications. Peptides were
accepted if they were confidently identified at≥95.0% probability
as evaluated by the local false discovery rate (FDR) algorithm. Pro-
teins were included if they were confidently identified at ≥99.0%
probability as assigned by the Protein Prophet algorithm incor-
porated in the software. Proteins containing shared or similar
peptides, and which could not be differentiated based on MS/MS
analysis alone, were grouped to satisfy the principles of parsi-
mony. Proteins, which confidently shared identified peptides were
grouped into clusters. Proteins were annotated using gene ontol-
ogy (GO) terms from NCBI. The protein identifications were
stringently filtered based on the presence of a minimum of two
peptides in all replicates. The relative abundances of proteins were
determined by conventional spectral counting and adjusted by tak-
ing the polypeptide length into account. Putative N -glycoproteins
in the proteome of the subcellular fractions were predicted in sil-
ico based on the presence of one or more sequons (NxT/S, x 6=P)
and a signal peptides (for secreted proteins) and/or transmem-
brane regions (for cell-surface and microsome proteins) using
prediction tools including SignalIP (v4.1) (36), Transmembrane
Hidden Markov Model (TMHMM v2.0) (37), PrediSi (38), and
Phobius (39). Mitochondrial and nuclear membrane proteins were
excluded as these are unlikely to enter the ER–Golgi glycosylation
pathway. Ambiguous assignments were manually checked (val-
idated or discarded) with information from Uniprot. Potential
sequons were obtained using NetNGlyc (40). These in silico predic-
tion tools generated lists of experimentally validated and putative
glycoproteins. The 100 most abundant glycoproteins in each sub-
cellular fraction were used to assess glycosylation site accessibility.
The contribution of these glycoproteins to the total glycoproteome
in each sample was estimated by multiplying the normalized spec-
tral count of the individual glycoproteins with their potential gly-
cosylation sites, a measure termed “sequon-weighted normalized
spectral count.”
SELECTION OF PDB 3D STRUCTURE FOR GLYCOSYLATION SITE
ACCESSIBILITY DETERMINATION
Three-dimensional protein structures were obtained from the
protein data bank (PDB) database2. If multiple structures were
available for a glycoprotein, the best match to the naturally occur-
ring variant was chosen by considering the following parameters
in a prioritized order: (1) high protein sequence coverage and res-
olution of the 3D structure, (2) source of protein (purified from
organism/tissue over artificial expression system), (3) known site-
specific mutations, (4) presence of artificial/natural ligands, and
(5) oligomerization of the solved 3D structure. The experimen-
tally obtained PDB structures used in this study were all based
2http://www.rcsb.org/pdb
on X-ray crystallography, Table S2 in Supplementary Material.
Where no experimentally determined structures were available
(43%), structure homologs were obtained from ProteinModel-
Portal3, Swiss-model repository4, or ModBase5. High sequence
homology was used as a selection criterion when choosing homol-
ogy model. The average sequence homology for all structures was
67%, which is considered very reliable for homology modeling
(41), Table S1 in Supplementary Material. 3D protein structures
were viewed with RasMol v2.7.5 (RasWin Molecular Graphics) for
visual inspection.
GLYCOSYLATION SITE ACCESSIBILITY DETERMINATION FROM
MATURELY FOLDED GLYCOPROTEINS
The glycosylation site solvent accessibility was determined by
measuring the accessibility to the individual asparagine residues
forming the glycosylation sites using NACCESS6 (42), an accurate
and frequently used solvent accessibility determination program
(19, 43–45). NACCESS calculates the atomic accessible area by pre-
dicting van der Waal’s interactions when a probe is rolled around
on the protein surface (46, 47). The maximum probe size offered
by the program (5 Å radius) was used as a default in this study to
simulate as closely as possible the accessibility of the glycosylation
enzymes to the glycosylation sites. NACCESS produces unit-less
and absolute accessibility values as the output format (denoted
“arb. units”), which are comparable between glycosylation sites
of different glycoproteins (19). Prior to the measurements of
site accessibility, any water molecules, sugars, ligands, and other
hetero-atoms/molecules, not part of the core polypeptide chain,
were removed from the protein surface. Negligible accessibility dif-
ferences were observed for the“native”and the monomeric form of
glycoproteins with quaternary structures (data not shown). Hence,
in the case of multimers, glycosylation site solvent accessibilities
derived from the monomeric structures were not considered in
the analysis.
STATISTICAL ANALYSIS
All relative abundances of N -glycans were presented as a percent-
age out of 100% as mean± SD. Glycosylation site accessibilities
were presented as mean± SEM to illustrate the potential spread
of mean instead of the individual data points, which can be hugely
influenced by the (local) accuracy and quality of the PDB struc-
tures. To overcome this potential issue of PDB“noise,”relative large
numbers of data points (n) were needed. Data were analyzed using
Prism v6 (GraphPad). One-way ANOVA analysis was performed
for statistical comparison between the three subcellular fractions
followed by post hoc Tukey’s tests. All p values were adjusted tak-
ing into account the multiple comparisons made and reported as
multiplicity adjusted p values. p< 0.05 was regarded as statistically
significant and indicated with “*.” Stronger statistical significance
was indicated as follows: **p< 0.01; ***p< 0.001; ****p< 0.0001.
Simple linear regression and corresponding correlation coeffi-
cients (R2) were obtained to evaluate the relationship between
3http://www.proteinmodelportal.org
4http://swissmodel.expasy.org
5http://modbase.compbio.ucsf.edu/modbase-cgi/index.cgi
6http://wolf.bms.umist.ac.uk/naccess/
www.frontiersin.org August 2014 | Volume 5 | Article 404 | 5
Lee et al. Differential Asn-accessibility generates subcellular-specific N -glycosylation
the degree of N -glycan processing in terms of glycan type and
expression of terminal glycan determinants and the glycosylation
site solvent accessibility.
RESULTS
SUBCELLULAR-SPECIFIC N -GLYCOSYLATION OF HUMAN BREAST
EPITHELIAL CELLS
Label-free quantitative N -glycome mapping of the secreted and
microsome (total membrane) subcellular glycoproteomes of a
panel of eight cultured human breast cells (i.e., MCF7, SKBR3,
MDA157, MDA231, MDA468, HS578T, HMEC, and MCF10A)
displaying diverse cellular features showed differential N -glycan
processing of the two fractions, Figure 1A. The glycoproteins
secreted into the cultured media consistently displayed a sig-
nificantly higher proportion of processed N -glycan types (i.e.,
hybrid, complex, and paucimannose) (74.2–95.0% mol/mol of
total N -glycome) than the high-mannose-rich microsomal sub-
cellular glycoproteomes (22.1–55.6%, p< 0.0001–0.05). Little, if
any, correlation between the N -glycan processing stage and the
cellular doubling time (R2= 0.13) or the protein secretion rate
(R2= 0.35), respectively, was detected of the secreted glycopro-
teomes across the cell line panel, Figure S1 in Supplementary
Material. No correlation was detected between the N -glycan
processing stage of the microsomal glycoproteins and the cel-
lular doubling time (R2= 0.04) or the protein secretion rate
(R2= 0.01).
In-depth, N -glycan profiling of the secreted, microsomal, and
cell-surface enriched glycoproteomes was carried out for MCF7,
MDA468, and MCF10A cells as representative cells for the breast
cell line panel. Differential N -glycan processing was evident as
exampled by the clear differences seen in the N -glycome m/z pro-
files of the three subcellular fractions of MCF7 cells, Figure 1B.
The cell-surface glycoproteins derived from MCF7 and MDA468
(but not MCF10A) cells were subjected to more N -glycan process-
ing than microsomal proteins (p< 0.01–0.05) and all the three
cell lines showed significantly increased abundance of the more
processed N -glycans on the secreted proteins (p< 0.0001–0.01),
Figure 1C.
SUBCELLULAR-SPECIFIC DISTRIBUTION OF N -GLYCAN
DETERMINANTS
To further evaluate the subcellular-specific distribution of com-
mon N -glycosylation determinants, which may be recognized
by different immuno-lectins, terminal α-mannose, α-fucose, and
α-sialic acid residues were mapped based on the obtained N -
glycome profiles, Figure 1D. As expected from the glycan type
distribution, terminating α-mannosylation was found to be sig-
nificantly reduced on the secreted and cell-surface proteins rel-
ative to the microsomal proteins. The α-fucosylation, primarily
of the α1,6-(core) type, and α2,3/6-sialylation were concomi-
tantly significantly higher in the secreted fractions than in the
cell-surface-enriched fraction (with the exception of fucosyla-
tion of MCF7) and in the microsomal fraction of all three
cell lines. Taking the incomplete subcellular fractionation into
account (see “Proteomics- and GO-Based Assessment of Sub-
cellular Fractionation”), we estimate that very little terminal α-
mannosylation is present on protein N -glycans in contact with
the extracellular environment in the investigated cells and that
little α-sialylation and α-fucosylation are carried by intracellular
(microsomal) N -glycoproteins.
PROTEOMICS- AND GO-BASED ASSESSMENT OF SUBCELLULAR
FRACTIONATION
In total, 2,297, 2,636, and 2,042 human proteins were identi-
fied across the three subcellular fractions in MCF7, MDA468,
and MCF10A, respectively. Putative N -glycoproteins fulfilling our
strict prediction criteria i.e., presence of the following: one or more
sequons (NxT/S, x 6=P); and signal peptides (for secreted pro-
teins); and/or transmembrane regions (for membrane-tethered
proteins) comprised significant proportions of the subcellular pro-
teomes (15.7–31.0%), Table S3A in Supplementary Material. The
GO terms “ER”,“Golgi/endosome/plasma membrane”, and “extra-
cellular” were used to evaluate the localization/origin of the glyco-
proteins identified in the subcellular fractions. In agreement with
a previous study (23), the GO annotation of the identified proteins
showed that the microsomes in general contained a high propor-
tion of ER-residing proteins, Figures 2A–C. Although the proteins
are only broadly, and possibly somewhat inaccurately, classified
on the basis of GO terms, the trends clearly indicated signifi-
cant enrichment, although not complete isolation, of the desired
proteins in the respective subcellular fractions. The ER-based
contribution to the microsome was supported by the fact that a sig-
nificant proportion of the high-mannose N -glycans identified in
this fraction were of the immature type i.e., Man9±Glc1 (MCF7:
35.3± 0.9%, MDA468: 40.2± 2.0%, and MCF10A: 31.8± 0.4%,
mol/mol of the total high-mannose N -glycans), Figure 2D (MCF7
data) and Figure S2 in Supplementary Material (MDA468 and
MCF10A data).
To further investigate the intracellular N -glycosylation and
confirm the presence of ER-rich microsomes, the N -glycome and
proteome of ER- and Golgi-enriched fractions of human colon
epithelial cancer cells (SW480) as prepared by the method of
sucrose density gradient centrifugation, were mapped and com-
pared to the microsome profiles derived from the same cells,
Figure S3A in Supplementary Material. Quantitative analysis of
four reliable and representative markers of the ER (i.e., 78 kDa
glucose-regulated protein, protein disulfide bond isomerase, cal-
reticulin, and protein transport protein Sec61 alpha isoform 1)
and Golgi (i.e., polypeptide N -acetylgalactosaminyltransferase 2,
β-1,4-galactosyltransferase 1, Golgi apparatus protein 1, and Golgi
membrane protein 1) compartments revealed a high abundance
of ER-specific proteins in the ER-enriched fraction, Figure S3B
in Supplementary Material. However, there was still a significant
presence of ER proteins in the Golgi-enriched and microsome frac-
tions. In contrast, the ER-enriched and microsome fractions were
essentially free of Golgi proteins, Figure S3C in Supplementary
Material. In line with our breast epithelial cell data, the proteins in
the ER-enriched fraction contained a significantly higher degree
of high-mannose (Glc0-1Man5-9GlcNAc2) (92%) N -glycans than
the proteins in the microsome (75%) and the Golgi-enriched frac-
tion (51%). Taken together, the data confirm that the microsomes
of human breast and colon epithelial cells predominantly contain
ER proteins and that such intracellular proteins mostly carry high-
mannose type N -glycosylation. Since the Golgi fraction contains
few, if any, ER proteins, it becomes clear that the majority of
post-ER N -glycans are of the complex type.
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FIGURE 1 | Secreted glycoproteins display more N -glycan type
processing than microsomal glycoproteins. (A) The N -glycomes of the
microsomal (top) and secreted (bottom) proteins of a panel of eight geno-
and phenotypically different cultured human breast epithelial cells (i.e.,
MCF7, SKBR3, MDA157, MDA231, MDA468, HS578T, HMEC, and MCF10A)
were profiled, see Table S1 in Supplementary Material for information of
investigated cells. The relative molar abundances (mean±SD) of more
processed N -glycans comprising the complex, hybrid, and paucimannose
type are presented in light red and the less processed N -glycans of the
immature and high-mannose type in green (inset). Subcellular-specific
N -glycosylation of boxed cell lines was investigated further in greater detail.
(B) Summed m/z profiles of the N -glycomes derived from microsomal (top),
cell-surface (middle), and secreted (bottom) proteins of MCF7 cells. Signals
corresponding to N -glycans have been assigned as less processed (green)
or more processed (light red) N -glycan types following the same
classification as in (A). (C) Relative molar distribution (mean±SD) of more
(right, hybrid/complex/paucimannose, light red bars) and less (left, high
mannose, green bars) processed N -glycan types of the microsomal (dotted
bars), cell-surface (brick), and secreted (banded) proteins of MCF7,
MDA468, and MCF10A. (D) Subcellular-specific distribution of the N -glycan
determinants. The proportion of terminal α-mannosylation, α-fucosylation,
and α-sialylation (non-reducing end) N -glycans of the total N -glycome
(mol/mol %) on the microsome, cell-surface, and secreted glycoproteomes
across MCF7 (i), MDA468 (ii), and MCF10A (iii) breast cell lines were
determined from the N -glycome profiles. N -glycans may terminate with
multiple monosaccharide determinants making the values sum to more
than 100%. For all panels: ns, not significant; *p<0.05; **p<0.01;
***p<0.001; ****p<0.0001.
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FIGURE 2 | (A–C) The subcellular proteomes of MCF7, MDA468, and MCF10A
breast epithelial cell lines were mapped according to GO terms into ER,
Golgi/endosome/plasma membrane, and extracellular region classifiers. This
confirmed enrichment, but not isolation, of cell-surface and secreted proteins
in the respective subcellular fractions. In addition, the classification confirmed
that the microsomes contained a significant proportion of ER-residing
proteins. (D) The subcellular distribution of the high-mannose glycan type
series on proteins derived from MCF7 into Man5, Man6, Man7, Man8,
Man9 ±Glc1, the latter representing immature N -glycans normally only
associated with intracellular ER N -glycosylation. See Figure S2 in
Supplementary Material for the subcellular distribution of the high-mannose
glycan type series of MDA468 and MCF10A.
DIFFERENTIAL Asn SITE ACCESSIBILITIES EXPLAIN
SUBCELLULAR-SPECIFIC N -GLYCOSYLATION
To investigate a possible link between the observed subcellular-
specific N -glycosylation and protein N -glycosylation site acces-
sibility, in silico assessment of site accessibility was performed of
the identified proteins predicted to be N -glycosylated. Due to the
laborious and time-consuming approach of determining glyco-
protein site accessibility (19), only the most abundant subset of
the putative N -glycoproteins observed in the subcellular fractions
were included in the accessibility assessment. The relative abun-
dances of the individual putative glycoproteins were calculated by
a conventional normalized spectral counting strategy; however,
the number of sequons of the individual proteins was factored
into the calculation to ensure a fair representation of heavily
and lightly N -glycosylated proteins. We call this term “sequon-
weighted normalized spectral counts.” Based on sequon-weighted
normalized spectral counts, the 100 most abundant glycopro-
teins uniquely present in the three subcellular fractions, which,
by weight, comprised 70–100% of the individual subcellular gly-
coproteomes, were used to assess glycosylation site accessibility,
Table S3B in Supplementary Material. The solvent site accessibili-
ties were determined using an established approach based on van
der Waal interactions of the asparagine residue of the glycosylation
sites to solvent (19). 3D-glycoprotein structures (experimental
or homology modeled) were available for approximately one-
third of the 189, 89, and 183 putative N -glycoproteins identified
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FIGURE 3 | (A) Glycosylation site accessibilities (unit-less, arbitrary values,
mean±SEM) of the microsomal (green), cell-surface (white), and secreted
(light red) proteins derived from MCF7, MDA468, and MCF10A breast
epithelial cell lines. (B) Correlation between the site accessibilities and the
N -glycosylation processing as measured by the more processed N -glycan
types (hybrid, complex, and paucimannose) as a molar proportion of the total
N -glycome for the three subcellular fractions. High correlation coefficients
(R2) indicate strong correlation.
uniquely in the microsome, cell-surface, and secreted fraction,
respectively, Figure S4 in Supplementary Material. This yielded
site-accessibility datasets covering in total 161 (microsome), 189
(cell-surface), and 236 (secreted) N -glycosylation sites from the
three cell types.
Differential site accessibilities were observed for the three sub-
cellular glycoproteomes for all three investigated breast cell lines,
Figure 3A (see also Figures S5A–C in Supplementary Material
for an alternative representation showing 95% confidence inter-
vals). Glycosylation sites of secreted glycoproteins were signif-
icantly more accessible [MCF7: 85.63± 35.47, n= 73; MD468:
85.44± 36.85, n= 112; MCF10A: 86.56± 33.54 (all unit-less
arbitrary values), n= 95] than sites on microsomal proteins
(MCF7: 59.44± 46.58, n= 32; MD468: 64.98± 46.99, n= 40;
MCF10A: 64.84± 40.97, n= 22, p< 0.01). In agreement with
the N -glycomes that carried a mixture of less processed high-
mannose and more processed N -glycan types, the sites of cell-
surface proteins were intermediately accessible: cell-surface sites
were either statistically similar in accessibility to the microso-
mal protein sites (MCF10A: 67.70± 37.66, n= 44) or similar to
the secreted protein sites (MCF7: 76.20± 38.13, n= 84; MD468:
85.95± 34.08, n= 40). For all three breast cell lines, the gly-
cosylation site accessibilities were strongly correlated with the
N -glycan processing as measured by their glycan type (MCF7:
R2= 0.94; MD468: R2= 0.75; MCF10A: R2= 0.92), Figure 3B.
Higher average glycosylation site accessibility of the secreted and
partly also the cell-surface glycoproteins resulted, as such, in
more N -glycan processing in terms of glycan type formation.
Other subcellular-specific N -glycosylation signatures including
core fucosylation, β-galactosylation, and α-sialylation were found
to correlate only weakly or not at all with glycosylation site acces-
sibility upon search for consistent trends across the three different
cell lines, Table S4 in Supplementary Material.
DISCUSSION
SUBCELLULAR-SPECIFIC PROTEIN N -GLYCOSYLATION OF HUMAN
CELLS
All N -linked glycoproteins synthesized by a given cell are processed
by a common glycosylation machinery. Despite this shared biosyn-
thetic machinery, we observed that a panel of human breast epithe-
lial cells of different geno- and phenotypes, reproducibly pro-
duced subcellular glycoproteomes with distinct N -glycosylation
signatures. The N-glycans attached to proteins enriched from the
cell-surface, and in particular the secreted glycoproteins, were sig-
nificantly more processed with respect to their glycan type (i.e.,
hybrid/complex/paucimannose) than the predominantly high-
mannose type microsomal proteins for all investigated cells. As
such, subcellular-specific N -glycosylation can be predicted to be
a general cellular feature not restricted to the investigated breast
epithelial cells. Deeper dissection of the intracellular organelle-
specificity of colon cell N -glycosylation supported this concept.
The capacity of human cells to generate multiple subcellular gly-
coproteomes displaying specific N -glycosylation profiles has, to
the best of our knowledge, not been systematically investigated.
The importance of cell-surface N -glycosylation for cell–cell
and cell–protein interactions has prompted several investigations
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of the cell-surface (alternatively termed plasma membrane)
N -glycosylation. High-mannose type N -glycans, in particular
Man8–9 structures, were previously reported to be the domi-
nating features of the plasma membrane of human embryonic
stem cells (48) and of cancer cells (49, 50). However, cell lysates
and total membrane fractions similar to our microsome prepa-
rations were used in these studies suggesting significant con-
tributions from intracellular high-mannose-rich ER-residing N -
glycoproteins (23). Hence, the actual cell-surface N -glycomes in
the previous work may not have been accurately captured. Specific
cell-surface enrichment methods such as biotinylation labeling
strategies used in this study or adhesion-based isolation meth-
ods (23) indicate that human cell-surfaces instead are generally
decorated with more processed N -glycan types.
Of the six cancerous breast cells investigated in this study,
only MCF7 and MDA468 displayed predominantly (>70%) high-
mannose N-glycans of the microsomal proteins. Approximately
equal distribution of high-mannose and the more processed N -
glycan types of microsomal proteins were detected in the remain-
ing four cancerous (SKBR3, MDA157, MDA231, and HS578T) and
the two non-cancerous cells (HMEC and MCF10A). In addition,
no consistent over-representation of high-mannose N -glycans
were detected for the secreted proteins derived from the cancer-
ous cell lines relative to the non-cancerous cell lines. Together this
indicates that high-mannose N -glycosylation is not linked directly
to tumorigenesis. Others have associated serum-derived high-
mannose N -glycoproteins to pathogenesis including cancer and
inflammation (5, 51); however, whether these under-processed
species are a result of leakage of intracellular glycoproteins as
a consequence of cell death or active cellular secretion from
intact cells remains to be described. Based on in-depth compar-
ative analysis of the N -glycomes derived from secreted proteins
of breast and colon epithelial cells of non-cancerous and can-
cerous nature, we have recently identified several tumor- and
sub-type specific N -glycosylation signatures amongst the complex
N -glycans including alterations of sialylation, α1,6-fucosylation,
and bisecting β1,4-GlcNAcylation (submitted) (52).
SITE ACCESSIBILITIES MECHANISTICALLY EXPLAIN
SUBCELLULAR-SPECIFIC N -GLYCOSYLATION
We have previously shown that solvent accessibility of the glycosy-
lation site of N -glycoproteins is an important factor in generating
protein- and site-specific N -glycosylation (19). We used literature-
based glycoprofiling of more than 100 mammalian glycoproteins
produced under different cellular and physiological conditions to
establish that site accessibility of maturely folded glycoproteins
correlates with N -glycan processing features including glycan type,
α1,6-fucosylation and β1,4/6-GlcNAc-branching. We emphasized
in that study that relatively large datasets were required to compen-
sate for the potential inaccuracy of the individual PDB structures
and the relative simplistic solvent accessibility assessment simulat-
ing the accessibility of the processing glycosylation enzymes to the
protein glycosylation sites.
Herein, we used a similar approach using our own N -
glycosylation data acquired from eight cell lines fractionated into
subcellular glycoproteomes to further explore the determining fea-
tures of site-specific N -glycosylation in the context of subcellular
localization of proteins. Homogenous cell cultures were an essen-
tial tool to ensure that the isolated subcellular glycoproteomes
were produced simultaneously under the same physiological con-
ditions of the glycosylation machinery. Although the N -glycomes,
as expected, varied considerably between the different cell lines,
our experimental data not only validated the strong correlation
of the N -glycan type and the glycosylation site accessibility of
maturely folded glycoproteins in agreement with our previously
report (19), but also mechanistically explained that subcellular-
specific N -glycosylation is driven by differences in site acces-
sibilities of the individual glycoproteins ending up at different
subcellular destinations, Figure 4. Intracellular (microsome) N -
glycoproteins receive little glycan processing of the high-mannose
intermediates as a result of limited site accessibility, whereas the
secreted N -glycoproteins are modified almost entirely to more
processed N -glycan types due to high site accessibilities. As such,
N -glycan processing may be a targeting signal or a requirement
for intracellular (ER–Golgi-residing) glycoproteins to translocate
to the surface for cell-surface integration/secretion via vesicles.
Keeping in mind there may be many exceptions to the molecular
trends presented here, it is tempting to view the glycosylation site
accessibility, and, thus, the N -glycan type, as a crude predictor of
subcellular location of human glycoproteins.
We have previously linked core fucosylation to glycosylation
site accessibility (19). Interestingly, glycosylation site accessibil-
ity alone could not explain the differential core fucosylation of
the subcellular fractionated proteins in our data: the secreted
proteins did not have a higher degree of core fucosylation of
complex/hybrid-type N -glycans than the cell-surface proteins
although the secreted proteins had significantly higher accessi-
bilities. This surprising observation may be explained by a pos-
sible advantage of the membrane-embedded cell-surface glyco-
proteins to achieve preferential interaction with the membrane-
bound fucosyltransferase 8 (FUT8) facilitating the addition of
α1,6-fucose residues to the chitobiose cores of N -glycans. Sol-
uble (luminal) glycoproteins may be less likely to interact with
FUT8. This explanation is congruent with our previous observa-
tion describing FUT8 discrimination of soluble N -glycoproteins
over membrane N -glycoproteins (19). Similar processing pref-
erence was not observed for the multiple processing enzymes
responsible for the formation of the glycan type. As expected, the
glycan modification more distal from the protein surface i.e., β-
1,3/4-galactosylation and α2,3/6-sialylation were not found to be
correlated with glycosylation site accessibility since the glycosyl-
transferases most likely have unhindered access to the substrates
relatively far from the protein surface. By the same token, we
cannot rule out that a more refined accessibility determination
approach, which not only takes into account the glycosylation
site solvent accessibility, but also the conjugated N -glycans (53–
56), may expose that other subcellular-specific N -glycan features
correlate with site accessibility. New developments in glycopro-
teomics may also support and strengthen these observations by
giving more accurate insight into the connectivity of glycosyla-
tion of the individual protein carriers (31). Finally, it should be
emphasized that although the subcellular glycoproteomes share
a common biosynthetic machinery, slightly different trafficking
rates and/or routes to their final destinations are factors that may
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FIGURE 4 | Subcellular-specific N -glycosylation is driven by differential
solvent accessibility to the N -glycosylation sites on maturely folded
glycoproteins. Consequently, the N -glycans of secreted, cell-surface, and
microsomal proteins receive high, intermediate, and low N -glycosylation
processing, respectively, and as a result, display distinct glyco-determinant
signatures.
contribute to yield distinct subcellular N -glycosylation. Other cel-
lular factors including the glycosylation enzyme activity or the
availability of nucleotide donors may also indirectly contribute to
subcellular-specific N -glycosylation by having differential effects
on the individual subcellular glycoproteomes.
SUBCELLULAR-SPECIFIC GLYCO-DETERMINANTS IN IMMUNITY
The distinct N -glycosylation signatures carried by the subcellu-
lar glycoproteomes may be functionally important in immunity if
we consider the key role of N -glycans as mediators for an effec-
tive innate and adaptive immune response through their specific
interaction with endogenous lectins. In addition, opportunistic
pathogens often use exposed N -glycan determinants as recep-
tors for adhesion using exogenous lectins (11). The observed
subcellular-specific glycosylation is here briefly discussed in the
context of glyco-immunity and infection; it is stressed that fur-
ther empirical evidence is required to validate these proposed
relationships.
We found that α-sialylation was a more abundant feature of
the secreted N -glycoproteins than cell-surface proteins. High sia-
lylation of secreted glycoproteins is essential to mask penultimate
galactose residues from being exposed and recognized by asialogly-
coprotein receptors, a C-type lectin (12). Thus, the high sialylation
of secreted glycoproteins may be a requirement to ensure pro-
longed circulation half-life. In addition, high sialylation of secreted
glycoproteins can act as a strong decoy for the less sialylated cell-
surface proteins, to which opportunistic pathogens are known to
adhere through sialic acid-recognizing I-type lectins (alternatively
termed siglecs) (57, 58). Displaying less-than-complete sialyla-
tion of the cell-surface proteins also ensures that a gradient of
biological activity toward endogenous siglecs for cellular signaling
and endocytosis (59) is maintained through structural diver-
sity, which may confer an immunological advantage to the host
cells (60).
The secreted N -glycoproteins were over-represented in α1,6-
core fucosylation relative to the cell-surface proteins. In line with
our previous observations, the higher degree of core fucosyla-
tion may serve to either mask hydrophobic patches to regulate
stability/solubility of the secreted N -glycoproteins (19) or to pro-
tect these more exposed proteins from proteolytic degradation
in the extracellular environment. It could be speculated that the
membrane-embedded nature of cell-surface glycoproteins would
make them more stable by not facing solubility issues in their local
environment and less vulnerable to proteolytic digestion, thereby
having less requirement for steric protection provided by a bulky
fucose residue proximal to the protein surface.
We and others have observed that α-mannose is an unusual ter-
minating structural determinant in the extracellular environment
(61, 62). This may partly be explained by the intracellular functions
of mannose (and glucose) terminating N -glycans (16, 17). The
presence of several mannose recognizing lectins in the extracellu-
lar environment including mannan binding protein (MBP), DC-
SIGN, and macrophage mannose receptors may be relevant in the
context of apoptosis when mannose terminating N -glycoproteins
are exposed to the extracellular environment. In particular, MBP is
a key player and a first line of defense in innate immunity, enabling
phagocytosis of apoptotic cells through its binding to exposed
immature or under-processed glycans or to pathogens carrying
mannosylated glycoproteins (63, 64). Hiding mannose inside cells
under physiological conditions could thus be viewed as being
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critical to avoiding the unnecessary onset of inflammation and
auto-immunity. The presence of extracellular α-mannosylation
would, as such, be indicative of pathophysiological conditions.
In support of this hypothesis, high-mannose containing glyco-
forms of intracellular adhesion molecule 1 and EGF receptor on
cell-surfaces were shown to contribute to endothelial inflamma-
tion (61) and correlated with poor prognosis of various cancers,
respectively (61, 62).
It has been noted that the structure and function of the protein
N -glycome is different within and outside human cells and that
these differences may be shaped by evolutionary forces (60). We are
the first to systematically investigate and mechanistically explain
some aspects of subcellular-specific N -glycosylation. We conclude
that human cells have developed protein structure-specific mech-
anisms including differential N -glycosylation site accessibilities
to generate subcellular glycoproteomes that display distinct N -
glycosylation phenotypes using a shared biosynthetic machinery.
Establishing this relationship is of general significance to glycobi-
ologists and in particular to molecular immunologists due to the
functional relevance of N -glycan determinants acting as ligands
for the spectrum of endogenous lectins involved in facilitating an
efficient immune response.
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